Vaccines against major ICU pathogens: where do we stand?

Area of Science:

• Microbiology
• Immunology
• Infectious Diseases

Background:

• Multidrug resistance in bacterial pathogens poses a global threat, rendering antibiotics ineffective, particularly for sepsis patients.
• The rise of antibiotic resistance necessitates the exploration of alternative nonantibiotic strategies for infection control.

Purpose of the Study:

• To review available vaccines against common community-acquired bacterial pathogens.
• To provide an overview of developing vaccines targeting prevalent hospital-acquired pathogens.
• To discuss the successes, challenges, and future prospects of bacterial vaccines.

Main Methods:

• Literature review of existing and developing bacterial vaccines.
• Analysis of vaccine efficacy against specific pathogens like pneumococci, meningococci, Clostridium difficile, Staphylococcus aureus, Acinetobacter baumannii, Klebsiella pneumoniae, and Pseudomonas aeruginosa.

Main Results:

• Conjugated vaccines against Haemophilus influenzae B and Streptococcus pneumoniae have demonstrated significant success, reducing invasive diseases and providing herd immunity.
• Ongoing vaccine development targets key nosocomial pathogens, addressing critical unmet needs in hospital settings.
• Despite successes, obstacles such as regional strain differences and antigen variability hinder vaccine cross-protectivity.

Conclusions:

• Bacterial vaccines represent an appealing prophylactic strategy against multidrug-resistant pathogens.
• While challenges persist, promising vaccine candidates are advancing in clinical development.
• Vaccination strategies are crucial for combating infectious diseases and mitigating the impact of antibiotic resistance.